# Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

> **NCT06260059** · PHASE4 · RECRUITING · sponsor: **Anita Saraf** · enrollment: 40 (estimated)

## Conditions studied

- Adult Congenital Heart Disease
- Heart Failure

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06260059
- **Lead sponsor:** Anita Saraf
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-17
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06260059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06260059, "Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06260059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*